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Background: Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic
(VTE) disease remain major complications following elective hip and knee surgery. This study compares three
chemoprophylactic regimens for VTE following elective primary unilateral hip or knee replacement, one of which
was designed to minimize risk of post-operative bleeding.
Methods: Patients were randomized and stratified for hip vs. knee to receive A: variable dose warfarin (first dose on
the night preceding surgery with subsequent target INR 2.0–2.5), B: 2.5 mg fondaparinux daily starting 6–18 h
postoperatively, or C: fixed 1.0 mg dose warfarin daily starting 7 days preoperatively. All treatments continued until
bilateral leg venous ultrasound day 28 ± 2 or earlier upon a VTE event. The study examined primary endpoints
including leg DVT, PE or death due to VTE and secondary endpoints including effects on D-dimer, estimated blood
loss (EBL) at surgery and hemorrhagic complications.
Results: Three hundred fifty-five patients were randomized. None was lost to follow-up. Taking 1.0 mg warfarin for
seven days preoperatively did not prolong the prothrombin time (PT). Two patients in Arm C had asymptomatic
distal DVT. One major bleed occurred in Arm B and one in Arm C (ischemic colitis). Elevated d-dimer did not predict
delayed VTE for one year.
Conclusions: Fixed low dose warfarin started preoperatively is equivalent to two other standards of care under
study (95 % CI: -0.0428, 0.0067 for both) as VTE prophylaxis for the patients having elective major joint replacement
surgery.
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Table 2 Exclusion criteria
1. Abnormal platelet count, prothrombin time (PT) or partial thromboplastin
time (PTT)
2. Surgery for acute fracture (<4 weeks), septic joint, or extraction
arthroplasty
3. History of VTE or documented hypercoagulation syndrome
4. Increased risk of hemorrhage, as from active gastric ulcer or urinary
tract bleed within the last year
5. Hemorrhagic stroke; brain, spinal, or ophthalmologic surgery in
previous 6 months
6. Liver enzymes or bilirubin greater than 2 x normal
7. Decreased renal function with GFR <30 ml/min.
8. Cancer in last year, other than localized cancers of the skin
9. Requires chronic anticoagulation
10. Requires chronic platelet function suppressive therapy




Table 1 Research design
ARM A:
Variable dose warfarin:
5.0 mg beginning the night before surgery,
followed by 5.0 mg the PM of surgery, and
then variable daily dose, (target INR 2.0-2.5)
until day 28 ± 2 follow-up.
ARM B:
Fondaparinux:
2.5 mg daily starting 6 or more hours
following surgery, but no later than 6 AM
the next day, or 6-8 h after epidural
catheter removal; continued until day 28 ± 2
ARM C:
Fixed low dose warfarin
1.0 mg daily beginning 7 days preoperatively,
and continued at 1.0 mg daily until day 28 ±
2 follow-up.
Bilateral, full leg, venous Doppler and ultrasound analysis 28 ± 2 following surgery
Follow-up phone calls at 6 and 12 months following surgery
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When initiated prior to elective surgery low dose war-
farin has been demonstrated prophylactic capacity
against VTE with low risk of hemorrhage [1–14]. War-
farin when given at 1 mg per day is known to increase
serum under-gamma-carboxylated osteocalcin and plas-
ma under-gamma-carboxylated prothrombin, without
change of prothrombin times or factor VII activity
[15]. It is critical in this pharmacologic format that low
dose warfarin be initiated prior to the surgical trauma,
thus allowing time for warfarin to partially suppress
the carboxylation of glutamic acid residues attached to
the cores of factors II, VII, IX and X [16]. This sequen-
tially reduces their calcium ion dependent function
[16–21] It is this mechanism which we believe reduces
the efficiency of calcium binding, thus slowing the effi-
ciency of clotting but not so much as to cause full
anticoagulation.
This study is a continuum of studies predicated upon
the concept that the clotting system can be kept in a
homeostatic balance, making it possible to avoid added
risk of bleeding while protecting patients from thrombo-
embolism [1–14]. Among these studies was a prospect-
ive pilot study of 100 patients in which patients planning
total hip replacement were randomized between two
arms, one with warfarin starting with 5.0 mg the night
prior to surgery followed by variable dose warfarin (tar-
get PT 1.3–1.5 x normal) and the other using 1.0 mg
of warfarin beginning seven days prior to surgery, and
both continuing for 30–45 days. There was no differ-
ence for incidence of venous thrombosis [8]. Another
was a retrospective study of patients undergoing pri-
mary (n = 833) or revision (n = 170) hip replacement
arthroplasty who received 1.0 mg of warfarin for seven
days prior to surgery, variable dose warfarin while in
hospital (target INR 1.5–2.0) followed by1.0 mg daily
until follow-up at 30–45 days. Of 1,003 patients, only 3
(0.3 %) had symptomatic VTE [11].
This current investigator-initiated, single-institution,
prospective, randomized, open-label assessor-blind study
study compared fixed low dose of warfarin to two con-
trol arms as chemoprophylaxis against VTE among
patients undergoing elective primary hip or knee re-
placement. Fixed low dose warfarin was initiated 7 days
prior to surgery so as to allow the necessary time for its
effects to be in place by the time of surgery. All patients
received the same optimal non-pharmacologic support.
We hypothesized that the three chemotherapeutic regi-
mens would yield equivalent clinical findings for these
patients. If confirmed as effective the fixed low dose
regimen should have minimal hemorrhagic potential
and would require less laboratory support, but with less
cost than the modern novel oral anticoagulants that are
also available [22].Methods
Research design
This was a prospective, randomized three-arm study in-
cluding two control arms (warfarin and fondaparinux in
standard doses) and a third arm using warfarin at 1.0 mg
per day starting seven days before surgery. Therapy was
continued until a VTE event occurred or until 28 ± 2 days
from day of surgery when bilateral leg ultrasounds were
performed. (see Table 1) All patients were called 6 and
12 months following their surgery to detect any delayed
complications or VTE events.
Fig. 1 Patient enrollment flowchart
Table 3 Results of randomization
Arm A Arm B Arm C Total
n n n n
Hip 54 64 55 173
Knee 64 54 64 182
Total 118 118 119 355
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death due to VTE. Secondary endpoints included fre-
quency of proximal vs. distal DVT, estimated blood loss
(EBL) at surgery, and hemorrhagic complications.
The hospital’s Institutional Review Board (IRB) ap-
proved this study. All patients gave signed informed
consent.
Randomization
Total randomized patient allocations were to be at 1:1:1
ratio for each arm at end of study. The randomization
was stratified for hip vs. knee surgery. A member of the
pharmacy department pulled randomized cards as pre-
pared by the statisticians. The results were communi-
cated to the Clinical Research Coordinator (CRC), who
then shared the results with the patients. Notice of con-
sent was place in the patient’s chart, along with pre-and
postoperative orders. Study diaries were then given to all
consenting patients.
Patient recruitment
Participants were recruited from among patients over
20 years of age planning elective primary unilateral total
hip or knee replacement surgery at an orthopedic spe-
cialty hospital. Exclusion criteria are demonstrated in
Table 2. There were no gender, ethnicity or race-based
restrictions.Surgical and postoperative care
Eleven orthopedic surgeons participated in this study.
The surgical, anesthesia and postoperative procedures
were according to the standardized procedures used in
our hospital. Patients had early post-operative ambula-
tion. All patients wore pneumatic compression stockings
while in-patient. Elastic compression stockings were pre-
scribed to be used after discharge until the follow-up ul-
trasounds. Hydroxyethyl starch (HES) 6 % was allowed
intraoperatively for case specific reasons. Use of platelet
function suppressive drugs, such a nonsteriodal anti-
inflamatory drugs (NSAIDs), was discouraged but not
prohibitied by the protool.
Laboratory monitoring
All patients receiving warfarin in hospital had PT mea-
sured daily. Thereafter, patients discharged on variable
dose warfarin had PT measurements twice per week. War-
farin doses were prescribed by the hospital’s Coumadin
Table 4 Baseline demographics
Demographics Arm A Arm B Arm C A vs B A vs C B vs C
p value p value p value
Hips % Male & Female 31.4/32.4 36.0/31.0 32.6/36.6 0.646 0.827 0.490
Age (yr. ± 1 SD) 59.5 (8.6) 60.5 (6.8) 58.9 (9.2) 0.764 0.939 0.553
BMI (± 1SD) 29 (4.5) 30 (4.6) 29.5 (5.6) 0.507 0.837 0.847
Knees % Male & Female 27.2/37.5 39.5/28.9 33.3/33.7 0.084 0.397 0.369
Age (yr. ± 1 SD) 63.5 (8.2) 63.3 (8.2) 62.3 (8.0) 0.985 0.694 0.791
BMI (± 1 SD) 30.9 (5.9) 31.2 (5.1) 30.8 (5) 0.954 0.993 0.915
Total cohort % Male & Female 29.3/35.4 37.7/29.7 32.9/34.9 0.111 0.621 0.263
Age (yr. ± 1 SD) 61.6 (8.6) 62 (7.7) 60.7 (8.7) 0.934 0.687 0.467
BMI (± 1SD) 30 (5.4) 30.6 (4.9) 30.2 (5.3) 0.618 0.960 0.783
Table 5 Baseline laboratory results
Laboratory tests ARM A ARM B ARM C A vs B A vs C B vs C
p value p value p value
Routine laboratory units (± 1 Standard Deviation)
Hips Hemoglobin 13.9 (1.2) 14.0 (1.4) 13.7 (1.5) 0.921 0.765 0.525
Platelets (x 1,000) 245.3 (51.8) 244.2 (53.8) 252.3 (47.0) 0.993 0.753 0.685
BUN 17.2 (5.0) 17.5 (4.8) 18.0 (7.3) 0.963 0.722 0.865
Creatinine 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.920 0.692 0.448
Bilirubin 0.5 (0.2) 0.5 (0.3) 0.5 (0.2) 0.689 0.914 0.434
ALT 9.3 (8.5) 11.9 (10.8) 11.5 (8.1) 0.294 0.432 0.962
AST 21.9 (7.0) 22.0 (6.3) 21.9 (5.8) 0.998 0.999 0.994
PTT 27.8 (2.3) 27.4 (2.4) 27.8 (2.2) 0.636 0.993 0.701
INR 1.02 (0.05) 1.01 (0.06) 1.02 (0.06) 0.800 0.099 0.814
Knees Hemoglobin 13.6 (1.5) 13.9 (1.5) 13.6 (1.3) 0.430 0.994 0.493
Platelets (x 1,000) 257.8 (59.9) 240.0 (47.0) 244.5 (54.6) 0.153 0.346 0.888
BUN 17.9 (5.0) 17.6 (5.4) 18.6 (5.7) 0.963 0.752 0.589
Creatinine 0.8 (0.2) 0.9 (0.2) 0.9 (0.2) 0.434 0.143 0.786
Bilirubin 0.4 (0.3) 0.5 (0.2) 0.5 (0.3) 0.416 0.934 0.638
ALT 12.6 (12.6) 12.8 (12.0) 12.2 (9.7) 0.995 0.970 0.943
AST 22.9 (8.7) 22.3 (8.0) 22.4 (6.6) 0.899 0.929 0.997
PTT 27.6 (2.4) 28.5 (2.3) 27.8 (1.8) 0.067 0.872 0.192
INR 1.00 (0.05) 1.02 (0.04) 1.02 (0.05) 0.217 0.289 0.985
Total cohort Hemoglobin 13.7 (1.4) 13.9 (1.4) 13.7 (1.4) 0.464 0.921 0.259
Platelets (x 1,000) 252.1 (56.5) 242.0 (50.1) 248.1 (51.2) 0.301 0.829 0.640
BUN 17.6 (5.0) 17.6 (5.1) 18.3 (6.4) 1.000 0.542 0.536
Creatinine 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.790 0.123 0.392
Bilirubin 0.5 (0.3) 0.5 (0.2) 0.5 (0.2) 0.292 1.000 0.293
ALT 11.1 (11.0) 12.4 (11.4) 11.8 (9.0) 0.600 0.853 0.905
AST 22.4 (8.0) 22.2 (7.3) 22.1 (6.2) 0.946 0.943 1.000
PTT 27.7 (2.3) 28.0 (2.4) 27.8 (2.0) 0.596 0.957 0.770
INR 1.01 (0.06) 1.02 (0.05) 1.02 (0.06) 0.767 0.563 0.943
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Table 6 Patient withdrawals from study
Arm A Arm B Arm C
Patients withdrawn from study before starting
study drug
1 3 5
Patients withdrawn from study after starting
study drug
0 3 1
Patients withdrawn before starting study
drug; completed ultrasound
1 7 2
Patients withdrawn after starting study
drug; completed ultrasound
1 4 2
Fig. 2 INR’s for patients on Arm C after taking 1 mg warfarin for
7 days before surgery
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Ratio (INR) 2.0–2.5. The patients on the 1 mg warfarin
study arm had PT measured weekly. D-dimer was tested
by flocculation and by quantitative assays upon admission
and at the 28 ± 2 day follow-up visits with the results are
reported as negative (0–500 μg/mL), indeterminate (500–
1,000 μg/mL), or positive (>1,000 μg/mL). (Diagnostica
Stago, American Bioproducts Co., Parsippany, New Jersey
07054).
Patient monitoring
Clinical Research Coordinators (CRCs) visited patients
daily during inpatient hospitalization. After discharge
the CRC’s called the patients weekly to monitor compli-
ance and for any complications. The patients were met
by the CRC’s again at the time of the follow-up ultra-
sound. Additionally, patients kept daily diaries of the
doses and times of administration of their study drug
along with any other drugs they were taking, and any
complications and return visits to doctors or hospitals.
Telephone interviews were conducted by the CRCs after
6 and 12 months to detect any delayed complications or
VTE events.
Examination for deep vein thrombosis and pulmonary
embolus
Patients underwent bilateral duplex sonography to evalu-
ate any clinical suggestions of DVT or if asymptomatic on
day 28 ± 2 following surgery. Gray scale, color, and spec-
tral Doppler sonography with augmentation were per-
formed of the bilateral common femoral veins, deep
femoral veins, superficial femoral veins, popliteal veins,
proximal greater saphenous veins, anterior and posterior
tibial veins, and peroneal veins. Three highly trained tech-
nologists were involved in this study applied the Practice
Guidelines and Technical Standards of the American Col-
lege of Radiology, revised 2010. Ventilation/perfusion lung
scan or computerized axial tomography angiogram was
performed for evaluation of symptoms of pulmonary em-
bolus. Radiology technicians and the radiologists were
blinded to patient randomization.
Quality assurance
The Protocol Committee reviewed data weekly. The Data
and Safety Monitoring Board (DSMB) examined blinded
data every three months with authority to stop the study if
deemed necessary.
Participant retention
Patients were removed from the study drug, but not
from the study, if they reached a composite endpoint or
if they elected to discontinue the study drug, including
those patients who required change in their anticoagula-
tion for ancillary medical reasons.Protocol violations and adverse events
The Protocol Committee reviewed in blinded fashion all
potential protocol violations and adverse events. The
likelihood that there be a relationship between the re-
ported events and the study drugs was assigned as being
not related, unlikely related, possibly related, probably
related or related. A major adverse event was defined as
one that required medical or surgical intervention while
in hospital, delayed discharge, or prompted return to of-
fice or hospital for reevaluation (whether or not inter-
vention was required).
Hemorrhagic complications were classified as major or
minor. A minor hemorrhage was one that was observed
but required no intervention, such as epistaxis or
venipuncture site hematoma. It may have been signifi-
cant enough to warrant discharge delay or prompt a visit
to the doctor or hospital, but with no intervention re-
quired. A major hemorrhage would include any fatal
bleed or symptomatic bleed into critical area or organ
requiring intervention.
Any major adverse event was reported to the IRB,
DSMB and if required to the Federal Drug Administration.
Statistical methods
The study analysis was based upon intention to treat
and thus all consented patients were included in the
analysis. The primary analysis was based on a dichotom-
ous outcome (i.e. VTE–yes/no) with VTE defined as the
Fig. 3 INRs for patients in Arm A receiving variable dose warfarin. These patients were studied twice per week during weeks 1, 2 and 3, as
indicated by “week 1a” and “week 1b”, etc
Fig. 4 All INRs for patients on Arm C
Bern et al. Thrombosis Journal  (2015) 13:32 Page 6 of 12composite of DVT or PE or death. Estimates of how
many patients were required in each arm to detect a dif-
ference were based on prior reported experiences in
similar studies. With the goal to demonstrate equality
for Arm C (upper one-sided 95 % confidence limit for
treatment Arm C minus standard treatment arms A and
B with the delta not to exceed 15 %), conservative esti-
mates of DVT rates from prior studies and powered to
90 %, it was concluded that 110 patients were needed
per group. As there were fewer endpoint events than ex-
pected in the three arms, the Odds Ratio was calculated
for the composite endpoints using an exact logistic re-
gression conditional analysis, a technique to be used
when the outcomes variable have no observations. The
non-inferiority analysis was completed using the Wald
non-inferiority test.
A statistician analyzed the outcomes for differences
between the study arms, differences within subsets (hip
and knee arthroplasty), and differences within arms A,
B and C for the primary and secondary endpoints.
Multivariate analysis is reported for age, gender, body
mass index (BMI), and use of hydroxyethyl starch or
NSAIDs. Primary outcome data are stratified for hip
vs. knee surgery, symptomatic vs. asymptomatic, and
popliteal vein and above (proximal) vs. more distal
veins. Secondary endpoints were analyzed for the pa-
tients as a total cohort. The p-values for all compara-
tive results were calculated.
This was an open label, assessor-blinded study. All au-
thors had access to the data.
Results
Patient recruitment, randomization and retention
There were 3,860 patients were identified for this study
by mailings. There was no response from 1,957 patients.
Figure 1 demonstrates the flowchart for the remaining
1,903 patients.Randomization was balanced between the three study
arms for hip vs. knee surgery, and for gender, age, BMI
and baseline blood studies. (see Tables 3, 4 and 5) Two
patients had rheumatoid arthritis. Both were among the
hip replacement patients. One of these had surgery for
steroid induced avascular necrosis. All other patients
had surgery for osteoarthritis.
Table 6 demonstrates the patients who withdrew com-
pletely from the study and those who withdrew from the
study drug but completed the bilateral leg ultrasound as
required by the protocol. All patients were included in
the Intention to Treat analysis.
Prothrombin times reported as International Normalized
Ratios (INR)
The INR’s on the day of surgery for patients in Arm C
after taking 1.0 mg of warfarin for seven days were ≤
1.3, with one exception to 1.5. (see Fig. 2) Fig. 3 demon-
strates the INR results for patients in Arm A. Each was
studied twice per week while on study and the warfarin
dose was adjusted according to protocol guidelines.
Fig. 4 demonstrates the weekly INR for all patients on
Arm C. Five out of 322 INR results that were greater
than 1.5.
Table 7 Patients receiving hydroxyethyl starch
Arm A Arm B Arm C A vs. B A vs C B vs C
n out of total n out of total n out of total p-value p-value p-value
Hips 21 out of 53 (39.6 %) 18 out of 54 (33.3 %) 17 out of 52 (30.4 %) 0.500 0.461 0.944
Knees 1 out of 62 (12.5 %) 2 out of 63 (25 %) 5 out of 62 (62.5 %) 0.576 0.131 0.251
Total 22 out of 115 (19.1 %) 20 out of 117 (17.1 %) 22 out of 114 (19.3 %) 0.687 0.974 0.664
Table 8 Composite endpoints
Arm A Arm B Arm C
n n n
DVT proximal 0 0 0
DVT distal 0 0 2
PE 0 0 0
Death on study 0 0 0
Exact Odds Ratios
Unadjusted Estimate 95 % Confidence Limits p-value
Odds Ratio (median unbiased)
Arm A vs. Arm C 0.397 0 – 3.344 0.480
Arm B vs. Arm C 0.387 0 - 3.259 0.476
Noninferiority Analysis of Risk Difference
Risk Difference Estimate 95 % Confidence Limits p-value*
Arm C vs. Arm A −0.0180 −0.0428 – 0.0067 <0.0001
Arm C vs. Arm B −0.0180 −0.0428 – 0.0067 <0.0001
*Using a noninferiority limit of -0.015
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Patients having hip replacement were more likely to be
given HES compared to those having knee replacement.
(p <0.05), but there were no differences among the three
study arms. (see Table 7) There were no differences
within the study groups relative to use of NSAID’s. (data
available).
Protocol violations
There were 73 minor protocol violations and 24 major
protocol violations, all equally distributed among the
study arms (data available) No study violation was asso-
ciated with an adverse event.
Composite endpoints
Complete bilateral leg ultrasounds were performed for
342 patients distributed equally in the study arms. (data
available) There were no patients with VTE at time of
discharge. Two patients in Arm C had delayed, asymp-
tomatic, distal ultrasound-detected deep vein throm-
bosis. One of these patients had knee replacement
surgery and the second had hip replacement surgery.
They were discharged on days 4 and 5 post-operative re-
spectively. There were no pulmonary emboli and no
deaths. The p-values, the Exact Odds ratios with associ-
ated confidence limits, the non-inferiority analysis and
the 95 % confidence limits are shown in Table 8.
Arm C was not to be different from Arms A and B.
Because Arm C was non-inferior to Arms A or B, we an-
alyzed equivalency between Arm C and the two arms
using the Wald Method for the non-inferiority. Analysis
of risk differences between the Arm C minus Arm A
and Arm B showed that Arm C is also equivalent to
both arm A and arm B, at an equivalency margin of
15 %. (p-value <0.0001; one-sided 95 % CI: -0.0428–
0.0067) Thus, there are no statistical differences between
Arm C and the other arms of the study.
Adverse events
There were no differences for the surgical estimated
blood loss (EBL) or transfusions given among the three
study groups. (data available) Patients taking NSAIDs
did not have increased hemorrhagic complications. (data
available) There were no surgery-related complications
such as fracture, dislocation or infection.More patients in Arm A reported a hemorrhagic
event as compared to Arms B and C. The risk of
reporting any hemorrhagic complication in Arm A was
1.29 times that of Arm B (95 % CI: 0.61–2.71), and was
1.54 times that of those in Arm C (95 % CI: 0.71–3.33).
While there were differences for patients having knee
replacement surgery these comparisons did not reach
statistical significance for the study groups. (see Table 9)
There were no differences of hemorrhagic complica-
tions using unadjusted and adjusted odds ratio related
to study arm or related to hip vs. knee surgery, adjusted
for effects of age, gender and use of HES and NSAID’s.
(see Tables 10 and 11) One Arm C patient developed
ischemic colitis complicated by gross hematochezia.
Despite his taking only 1 mg warfarin daily the INR
was prolonged. He was then found to have homozygous
vitamin K epoxide reductase–1 (VKORC-1) genome
disorder. The event was managed and he remained on
study.
Four major adverse events occurred. Table 12 demon-
strates the distribution of these events as being possibly
related, probably related or related to study drugs. The
two “probably related” leg hematomas occurred while
the patients were in the hospital. The other two events
occurred following discharge from the hospital.
Table 9 All hemorrhagic complications including all minor and major bleeds
Arm A Arm B Arm C A vs. B A vs C B vs C
n out of total n out of total n out of total p-value p-value p-value
Hips 9 out of 54 15 out of 54 6 out of 55 0.169 0.386 0.030
(16.7 %) (27.8 %) (10.9 %)
Knees 20 out of 64 8 out of 64 12 out of 64 0.013 0.105 0.333
(31.2 %) (12.5 %) (18.7 %)
Total 28 out of 118 23 out of 118 18 out of 119 0.347 0.070 0.375
(23.7 %) (19.5 %) (15.1 %)
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Patients having knee replacement were more likely to
have elevated D-dimer at the completion of the study
compared to those having hip surgery. (p <0.0001) (see
Table 13) There were no differences relative to the arms
of the study. There were no delayed onset VTE events
after 6 and 12 months from completion of study.
Discussion
Patients given no anticoagulants after hip or knee
arthroplasty experience high rates of postoperative VTE
[23–28]. Heretofore, commonly used anticoagulants re-
duced the frequency of postoperative VTE to 4–6 %. A
meta-analysis of modern low molecular weight heparins,
oral Xa inhibitors or oral IIa inhibitors included 47 clin-
ical trials and observational studies involving 44,844 pa-
tients demonstrated rates of symptomatic DVT prior to
discharge of 1.09 % for patients having TKA and 0.53 %
for patients having THA, with heterogeneity of results
among the included reports [29]. The current study
shows that our fixed low dose warfarin regimen approxi-
mates the same level of benefit.
The two agents used in this current study as controls







Both 1.29 (0.61-2.71) 0.709
Hip 0.45 (0.14-1.42) 0.236
Knee 3.18 (1.07-9.45) 0.034
Fixed dose warfarin vs. variable
dose warfarin
Both 0.83 (0.38-1.84) 0.854
Hip 0.38 (0.12-1.24) 0.134
Knee 1.78 (0.57-5.62) 0.463
Fixed dose warfarin vs.
fondaparinux
Both 0.65 (0.30-1.40) 0.384
Hip 0.84 (0.23-3.10) 0.946
Knee 0.56 (0.21-1.47) 0.338care agents available for DVT prophylaxis. Variable dose
warfarin has been used for many years, and is effective
with the current target range of INR [30, 31]. Fondapari-
nux, a synthesized pentasaccaride with anti-factor Xa ac-
tivity, was among the newer agents with VTE prophylaxis
activity when this study was designed [22, 32–35].
As in our previous orthopedic studies and as with
other investigators we selected a preoperative lead-time
of 7 days for the fixed low dose warfarin used in this
study [8, 11, 36, 37]. In an earlier central venous catheter
study we choose 3 days [6]. We would not expect this
low dose warfarin therapy to succeed if started following
surgery, even though in one series it did succeed even
when therapy was begun after central venous catheter
insertion [12, 38–41].
There were two previous smaller but similarly struc-
tured studies that derived negative results for low dose
warfarin following major orthopedic surgery. Poller, et al.,
in a report of 68 evaluable patients randomized to receive
either warfarin 1 mg daily starting 7 days preoperatively or
5,000 units heparin starting 2 h preoperatively, with ven-
ography as the diagnostic tool [36]. Fordyce, et al., studied
148 patients having primary hip replacement surgery were
randomized to take 1 mg warfarin starting 7 days prior toTable 11 Estimate of treatment effect of all hemorrhagic
complication stratified for hip vs knee adjusted for effects of




Hip Fondaparinux vs. variable dose
warfarin
0.45 (0.14-1.44) 0.238
Fixed dose warfarin vs. variable
dose warfarin
0.40 (0.12-1.32) 0.170
Fixed dose warfarin vs. fondaparinux 0.89 (0.24-3.3645) 0.978
Knee Fondaparinux vs. variable dose
warfarin
3.45 (1.15-10.32) 0.022
Fixed dose warfarin vs. variable
dose warfarin
1.78 (0.56-5.68) 0.471
Fixed dose warfarin vs. fondaparinux 0.52 (0.20-1.36) 0.248
Table 12 Major complications related to study drugs
Relationship to study drug n Description Study arm
Possibly related 1 Painless hematochezia following hard bowel movement (minor) B
Probably related 1 Hematoma, operative leg, from post-op trauma (minor; delayed discharge) B
1 Hematoma evaluated, no intervention required (minor; delayed discharge) B
Related 1 Hemorrhage with ischemic colitis. INR prolonged on 1 mg warfarin C
per day due to VKORC-1 genome disorder. (major; readmitted to hospital)
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beled fibrinogen uptake (with venography confirmation
for positive femoral vein uptake) was used for detec-
tion of DVT [37].
Differences in outcomes may be dependent upon the
DVT detection techniques applied. Color Doppler ultra-
sound was used in this study to detect DVT. Ultrasound
imaging is accepted for diagnosing DVT with sensitivity
and specificity for detection of proximal deep vein
thrombosis is over 95 %. In studies of asymptomatic pa-
tients, the sensitivity the test has been variable. Neverthe-
less, a single negative complete lower limb examination is
considered sufficient to exclude clinically important DVT
[42–44]. New symptoms always require further imaging.
In the current study patients were called at 6 and
12 months to detect any delayed symptomatic VTE events
in order to detect any false negative results.
On the other hand, venography, often considered the
gold standard for DVT detection studies, is far from the
ideal diagnostic procedure. Venography-dependent stud-
ies often have significant numbers of patients who never
get the venogram, have unilateral studies instead of bilat-
eral studies, or are rejected by the adjudicating commit-
tees as technically inadequate [24, 45–50]. Venography
also involves added risks for patients with allergic and
renal reactions, skin necrosis if contrast dye extravasates
and post-injection phlebitis in up to 2 % of patients in
whom conventional ionic contrast agents are used. Even
with use of lower osmolar contrast agents, minor sideTable 13 Changes of D-dimer from baseline negative/indeterminate
Changed from 0 – 999 at baseline to >1,000 after 28 ± 2 da
Yes No p
n (%) n (%)
Hips 45 (31.5 %) 98 (68.5 %) <
Knees 116 (70.7 %) 48 (29.3 %)
Patients with elevated D-dimer (>1,000 μg/dL) at follow-up, stratified for kne
Arm A Arm B A
Knees 12 of 47 (25.5 %) 15 of 50 (30.0 %) 1
Hips 41 of 54 (75.9 %) 38 of 59 (64.4 %) 3
Total 53 of 101 (52.5 %) 53 of 109 (48.6 %) 5effects occur in about 20 % of patients undergoing venog-
raphy. Fibrinogen scanning may have been supersensitive.
Also, the current study was performed in a hospital with
a high volume of joint replacement surgery, wherein opti-
mal non-pharmacologic DVT prophylaxis is also applied
along with chemoprophylaxis. Patients are told to discon-
tinue smoking and estrogen supplements prior to surgery,
to walk the day of surgery, and wear bilateral pneumatic
compression stockings in hospital followed by elastic com-
pression stockings after discharge until follow-up visits.
Perhaps some of these elements may contribute to differ-
ences between the study outcomes.
There are clinically relevant elements within any study
that cannot be stratified or controlled. In this study tour-
niquets were used for all patients having knee replace-
ment, and it is assumed that the time the tourniquets
were applied was equal for each study group [50]. Vol-
ume expansion by crystalloids can influence post-
operative coagulation; it is assumed that the volume ex-
pansions were equivalent for each study group [51]. HES
can have effects upon the clotting system [52, 53]. There
were no differences for the use of HES among the three
arms of this study. Also, as there are over 100 drugs,
foods and supplements reported to interfere with plate-
let function, with unclear clinical significance for most,
it would have been difficult to control for all of these
agents [54]. It was decided by the protocol writing com-
mittee to track and analyze six of the more commonly
used NSAIDs.to >1000 μgm/dl after 28 ± 2 days
ys
-value for hip vs. knee
0.0001
e vs. hip and study arm
rm C A vs. B A vs. C B vs. C
p-value p-value p-value
8 of 46 (39.1 %) 0.624 0.163 0.348
7 of 51 (72.5 %) 0.185 0.693 0.362
5 of 97 (56.7 %) 0.577 0.551 0.247
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for acute DVT or PE has been previously reported to be
predictive of relapse of VTE. In one such study following
one month of therapy for DVT, 39 % of patients had ele-
vated D-dimer and seven of these patients went on to
have recurrent VTE [55]. There is also increasing recog-
nition that longer prophylactic therapy is beneficial in
the post-operative setting [56–62]. The current study
prescribed that all study patients have measurements of
D-dimer at the end of the treatment. No patient had de-
layed onset VTE when called 6 months and 12 months
following completion of one month of therapy. Thus, in
this study a positive D-dimer at the conclusion of ther-
apy had no predictive value for delayed onset VTE after
prolonger therapy of one month.
This proof of concept study builds upon prior studies
examining low dose schedules for postoperative VTE
chemoprophylaxis with warfarin. Trail limitations in-
clude that this is a single institution, open label but
assessor-blind study study. A similar multi-institutional
study with a larger number of patients would be wel-
comed. Perhaps it would also be useful to attempt the
next such study with combined Doppler ultrasound and
venography detection for DVT to confirm adequacy of
Doppler ultrasound.
In conclusion, the three regimens in this study offer
effective prophylaxis against thromboembolic disease
following elective arthroplasty of hips and knees. It ap-
pears that fixed low dose warfarin when used as de-
scribed is equivalent to two of the more intense
regimens. By extending postoperative anticoagulation to
four weeks there appears to be less chance for delayed
VTE, even if there is a positive D-dimer at conclusion of
treatment. Each regimen carries some risk and some in-
convenience for the patient. The fixed low dose warfarin
regimen herein described saves the patients the incon-
venience of multiple blood draws, but does not eliminate
that need completely, as demonstrated in our patient
with vitamin K epoxide reductase genome disorder.
Nevertheless, it should carry minimal hemorrhagic po-
tential and require reduced laboratory support. It should
be less expensive and easier to administer than other
protocols using anti-Xa and anti-IIa agents, which has
implications for health care costs.
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